Home Use Lancing Devices Market Research, 2033
The global home use lancing devices market was valued at $359.5 million in 2023, and is projected to reach $537.8 million by 2033, growing at a CAGR of 4.1% from 2024 to 2033. A rise in the prevalence and incidence of diabetes globally is expected to drive the market growth.
Market Introduction and Definition
An instrument having a lancet is called a blood-sampling device, or lancing device. It is most commonly used by diabetic patients during blood glucose monitoring. A lancet, often called a prick, finger prick, or finger stick, is a tiny needle contained in a plastic moulded component that is used to pierce skin to get a blood sample. The needle is very small and thin, but big enough for a drop of blood to be drawn. Lancets can be used alone or with a lancing device. When using a lancet, a lancing device is utilized to help make the pricking process less painful and easier. Different skin thicknesses can have different skin penetration depths. Home use lancing devices are majorly used by diabetic patients for glucose monitoring.
Key Takeaways
- The home use lancing devices market size study covers 20 countries. The research includes a segment analysis of each country in terms of value for the projected period.
- More than 1, 500 product literatures, industry releases, annual reports, and other such documents of major home use lancing devices industry participants along with authentic industry journals, trade associations' releases, and government websites have been reviewed for generating high-value industry insights.
- The study integrated high-quality data, professional opinions and analysis, and critical independent perspectives. The research approach is intended to provide a balanced view of global markets and to assist stakeholders in making educated decisions in order to achieve their most ambitious growth objectives.
Key Market Dynamics
The home use lancing devices market growth is due to the rise in diabetes globally and other conditions requiring regular blood monitoring, such as hyperlipidemia and hemophilia, which has significantly increased the demand for home-use lancing devices. Regular blood glucose monitoring is essential for managing diabetes, making lancing devices a critical tool for patients. In addition, according to the World Health Organization in 2023, about 422 million people worldwide have diabetes, the majority living in low-and middle-income countries. Both the number of cases and the prevalence of diabetes have been steadily increasing over the past few decades. Moreover, according to the International Diabetes Federation, by 2045, it is estimated that 1 in 8 adults, approximately 783 million, will be living with diabetes, an increase of 46%.
Rise in awareness about the importance of monitoring blood glucose levels has led to more people, including those with pre-diabetes or at risk of developing diabetes, adopting home use lancing devices. There is a growing trend towards self-monitoring and home-based healthcare, driven by the desire for greater autonomy in managing health. This shift is particularly significant for chronic disease management, where continuous monitoring is necessary. The rise of telemedicine and remote health monitoring has further driven the home use lancing devices market size. Patients can now share their blood glucose readings with healthcare providers from home, facilitating continuous care without frequent visits to a clinic.
Furthermore, technological advancements have led to the development of more sophisticated, user-friendly lancing devices, thereby driving the home use lancing devices market forecast. Features such as adjustable depth settings, painless lancing, and digital integration make these devices more appealing to consumers. Innovations focused on reducing the pain associated with lancing have made these devices more attractive for regular use. This is especially important for individuals who need to test their blood multiple times a day.
The availability of more affordable lancing devices has made them accessible to a larger segment of the population. As the technology matures, costs have decreased, making these devices a viable option for more consumers. The increased availability of lancing devices through various distribution channels, including pharmacies, online retailers, and others, has made it easier for consumers to purchase. Thus, such factors are expected to drive the home use lancing devices market growth.
Parent Market Overview
Point-of-care glucose testing is a type of medical testing that measures blood glucose levels at the point of care or at the bedside of the patient, rather than sending blood samples to a laboratory for analysis. Point-of-care glucose testing is commonly used in the management of diabetes, a chronic condition in which the body is unable to properly regulate blood glucose levels. Point-of-care glucose testing products include strips, lancets and lancing devices, and meters. The global point-of-care glucose testing market size was valued at $3 billion in 2022, and is projected to reach $4.8 billion by 2032, growing at a CAGR of 4.8% from 2023 to 2032.
Point-of-care Glucose Testing Market, 2022 & 2032
2022 | 2032 |
3 billion | 4.8 billion |
Market Segmentation
The home use lancing devices market analysis is segmented into type, application, distribution channel, and region. On the basis of type, the market is categorized into standard lancet, safety lancet, and others. On the basis of application, the market is categorized into glucose testing, cholesterol testing, and others. On the basis of distribution channel, the market is categorized into online channel and offline channel. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Regional/Country Market Outlook
North America accounted for a major home use lancing devices market share owing to the presence of major players, high prevalence of diabetic population, rise in disposable income, and high adoption rate of technologically advanced products.
However, ?Asia-Pacific home use lancing devices market share is estimated to grow with the highest CAGR during the forecast period, owing to the higher prevalence of diabetes and cholesterol among population, which leads to high adoption of such products.
Industry Trends
- Manufacturers are concentrating on creating lancing instruments with characteristics including smoother puncture mechanisms, vibration technologies, and finer gauge needles that reduce pain. Advanced technology devices that lessen pain perception are growing in popularity.
- The number of people managing long-term illnesses like diabetes at home has raised the need for dependable, user-friendly lancing equipment. The increased emphasis on self-monitoring health measures and home-based healthcare is driving this trend.
Competitive Landscape
The major players operating in the home use lancing devices industry are Medtronic Plc, Integra LifeSciences Corporation, Unilife Corporation, LifeScan, Novo Nordisk A/S, Owen Mumford Ltd, Ypsomed AG, F. Hoffmann-La Roche Ltd, Terumo Corporation, and ARKRAY Inc.
Key Sources Referred
- National Center for Biotechnology Information
- World Health Organization (WHO)
- National Library of Medicine
- The United States Food and Drug Administration
- U.S. Department of Health & Human Services
- Centers for Disease Control and Prevention
- GOV.UK
- Australian Institute of Health and Welfare
- International Diabetes Federation
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the home use lancing devices market analysis from 2024 to 2033 to identify the prevailing home use lancing devices market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the home use lancing devices market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global home use lancing devices market trends, key players, market segments, application areas, and market growth strategies.
Home Use Lancing Devices Market , by Type Report Highlights
Aspects | Details |
Market Size By 2033 | USD 537.8 Million |
Growth Rate | CAGR of 4.1% |
Forecast period | 2024 - 2033 |
Report Pages | 280 |
By Type |
|
By Application |
|
By Distribution Channel |
|
By Region |
|
Key Market Players | Ypsomed AG, LifeScan, Unilife Corporation, Integra Lifesciences Corporation., F. Hoffmann-La Roche Ltd, Owen Mumford Ltd, ARKRAY Inc, Medtronic Plc, Terumo Corporation, Novo Nordisk A/S |
Rise in diabetes is the upcoming trend of home use Lancing devices market in the globe.
Glucose Testing is the leading application of home use Lancing devices market.
North America is the largest regional market for home use Lancing devices market.
The global home use lancing devices market was valued at $359.5 million in 2023, and is projected to reach $537.8 million by 2033, growing at a CAGR of 4.1% from 2024 to 2033.
The major players operating in the home use lancing devices market are Medtronic Plc, Integra LifeSciences Corporation, Unilife Corporation, LifeScan, Novo Nordisk A/S, Owen Mumford Ltd, Ypsomed AG, F. Hoffmann-La Roche Ltd, Terumo Corporation, and ARKRAY Inc.
Loading Table Of Content...